Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) was the target of a large decrease in short interest in December. As of December 29th, there was short interest totalling 1,464,128 shares, a decrease of 15.0% from the December 15th total of 1,723,304 shares. Currently, 2.0% of the shares of the stock are short sold. Based on an average daily volume of 238,293 shares, the short-interest ratio is presently 6.1 days.

Matinas BioPharma (MTNB) opened at $1.27 on Tuesday. Matinas BioPharma has a fifty-two week low of $1.01 and a fifty-two week high of $3.99. The stock has a market capitalization of $118.05, a PE ratio of -3.43 and a beta of 0.69.

Matinas BioPharma (NYSEAMERICAN:MTNB) last issued its earnings results on Wednesday, November 15th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. Matinas BioPharma had a negative return on equity of 195.09% and a negative net margin of 7,558.92%. The business had revenue of $0.05 million during the quarter, compared to analysts’ expectations of $0.05 million.

A hedge fund recently bought a new stake in Matinas BioPharma stock. Yellowstone Partners LLC bought a new position in Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 143,914 shares of the company’s stock, valued at approximately $190,000. Yellowstone Partners LLC owned approximately 0.16% of Matinas BioPharma as of its most recent SEC filing.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at

About Matinas BioPharma

Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.

Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with's FREE daily email newsletter.